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 Low PlGF at 
presentation with suspected preeclampsia 
identifies a severe phenotype of disease
 The use of PlGF testing leads to a reduction in 
severe maternal adverse outcomes
 PlGF testing increases antenatal surveillance of women at risk of complications of 
preeclampsia
 PlGF testing does not appear to cause an increase in preterm delivery rates
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Abstract
Objective: Placental growth factor testing decreases time to recognition of preeclampsia and may 
reduce severe maternal adverse outcomes. This analysis aims to describe the clinical phenotype of 
women by PlGF concentration, and to determine the mechanism(s) underpinning the reduction in 
severe maternal adverse outcomes in the PARROT trial, in order to inform how PlGF testing may be 
optimally used within clinical management algorithms.
Study Design: This was a planned secondary analysis from the PARROT trial that compared revealed 
PlGF testing and management guidance with usual care in the assessment of women with suspected 
preterm pre-eclampsia. 
Main Outcome Measures: maternal and perinatal outcomes following stratification of women by 
trial group, and measured PlGF concentration.
Results: 1006 women were included. PlGF <100pg/ml identified women with more marked 
hypertension, increased adverse maternal outcomes and preterm delivery rates, and higher rates of 
small for gestational age infants. There was a reduction in adverse maternal outcomes in women 
whose results were revealed when PlGF levels were 12-100pg/ml compared to usual care (3.8% vs 
6.9%; aOR 0.15(95% CI 0.03-0.92). There was no significant difference in gestation at delivery 
between concealed or revealed groups in any PlGF categories.
Conclusion: Low PlGF concentrations are associated with severe preeclampsia. The reduction in 
severe adverse maternal outcomes may be mediated through quicker diagnosis and intensive 
surveillance, as recommended by the management algorithm for those at increased risk. PlGF is 
particularly beneficial in those who test 12-100pg/ml, as these may be women with silent multi-
organ disease who otherwise may go undetected.
Keywords: preeclampsia, PlGF, hypertension in pregnancy, diagnostic testing
Abbreviations: PlGF; placental growth factor, NICE; National Institute of Health and Care Excellence, 
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Introduction
Preeclampsia complicates around 3% of singleton pregnancies, with hypertension affecting 10% of 
pregnant women.1-3 Preeclampsia is associated with a high risk of pregnancy complications including 
iatrogenic preterm birth, maternal and perinatal morbidity, and perinatal mortality.4-7
The placenta plays a central role in the pathogenesis of preeclampsia. Studies of placentally-derived 
angiogenic factors, such as Placental Growth Factor (PlGF) and soluble fms-like tyrosine kinase-1 
(sflt-1) have led to their development as adjuncts to diagnosis and prognosis.8,9 Evidence from 
prospective cohort studies has shown that angiogenic factors have good test performance for 
identifying preterm preeclampsia.10 11 These studies included women in whom angiogenic factor 
concentrations were concealed to carers. A recent randomised trial (PARROT) of 1023 women 
evaluated revealed PlGF measurement with a clinical management algorithm against usual care, 
forming one of the largest studies of angiogenic factors in the management of suspected preterm 
preeclampsia. In this trial there was a clinically important reduction in time to diagnosis of 
preeclampsia with a concurrent reduction seen in severe maternal adverse outcomes with revealed 
PlGF testing.12
The aim of this secondary analysis of the PARROT Trial was to describe clinical phenotypes of 
pregnancies by measured PlGF concentration. The analysis also assesses how PlGF measurement 
may have impacted on clinical outcomes, to inform understanding of the mechanism of benefit. We 
sought to determine how PlGF testing may be optimally used within clinical management 
algorithms, by evaluating effect of PlGF testing across women categorised by their PlGF level.  We 
focussed statistical testing on mechanistic questions related to how revealing an abnormal result 
might drive change in processes or pathways of care. 
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Methods
This was a planned secondary analysis of the PARROT trial, a multicentre stepped wedge cluster 
randomised controlled trial (ISRCTN 16842031), approved by the London South East Research Ethics 
Committee (15/LO/2058). Women were recruited from 11 centres with singleton pregnancies and a 
live fetus from 20+0 to 36+6 weeks’ gestation with suspected preeclampsia. Suspected preeclampsia 
was defined as new onset or worsening of existing hypertension, proteinuria, epigastric or right 
upper quadrant pain, headache with visual disturbances, altered maternal biochemistry or fetal 
growth restriction. Women were excluded if they had a confirmed diagnosis of preeclampsia at 
presentation. Randomisation was to intervention or control groups, and this occurred at cluster 
level, in a stepped wedge design.
Women in the control group received usual care following local hospital practice based on 2010 
National Institute of Health and Care Excellence (NICE) guidance on the management of 
hypertension in pregnancy,13 with an additional blood sample taken for concealed PlGF testing. 
National guidance included treatment with oral labetalol, nifedipine or methyldopa if above the 
blood pressure target range, a blood pressure target of less than 150/100 mmHg on treatment, 
twice weekly blood pressure and urine checks in women with gestational hypertension, admission to 
hospital and delivery at 37 weeks’ gestation for those with preeclampsia. Women in the intervention 
group received revealed PlGF testing integrated into a standard clinical management algorithm 
based upon national guidance (figure S1). Women were individually consented to participation in the 
trial. A single PlGF blood sample was taken from each woman at presentation.
All blood samples were processed at each unit on a Triage (Alere, San Diego, CA, now Quidel 
Cardiovascular Inc., San Diego, CA) instrument. Strict logs of quality control assessment were kept. 
Staff performing the assay were trained by the trial team and followed a standard operating 
procedure. The test is CE-Marked and is approved for use in countries recognising the CE Mark. This 
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clinical study was conducted in the European Union (U.K.) and investigated a clinical application 
approved under the product’s CE Mark.
 
Outcomes
Outcomes were collected until the primary postnatal discharge of the woman and infant pair from 
secondary care services. The primary outcome for the PARROT trial was the time from presentation 
with suspected preeclampsia to having a diagnosis of preeclampsia documented in the clinical notes. 
Maternal outcomes for this planned secondary analysis were a composite of severe maternal 
adverse outcomes as defined by the fullPIERS consensus,14 systolic blood pressure ≥ 160mmHg, 
progression to severe preeclampsia (independently adjudicated),15 placental abruption, mode and 
onset of delivery, use of medication, proportion of women reaching the diagnostic criteria 
(irrespective of clinical documentation) for preeclampsia16. These outcomes matched those used for 
the primary trial analysis.  
Perinatal outcomes included gestation at delivery, preterm birth below 37 weeks’ gestation, 
birthweight and birthweight centile,17 a composite of severe perinatal adverse outcomes (number of 
babies with one or more of the following: intraventricular haemorrhage, seizures, retinopathy of 
prematurity, respiratory distress syndrome, bronchopulmonary dysplasia, necrotising enterocolitis 
stage 2 and 3,18 stillbirth, early neonatal death and late neonatal death to 28 days), neonatal unit 
admission, perinatal death (stillbirths from 24 weeks’ gestation to deaths up to seven completed 
days after birth) and late neonatal death (deaths between 8 and 27 completed days of life).
Sample Size
The sample size was determined for the main PARROT trial.12 All women who participated in the trial 




Women were stratified by their measured PlGF concentration into the following predetermined 
groups: PlGF ≥100pg/ml – determined as ‘normal’; PlGF 12-99pg/ml, equivalent to <5th centile for 
gestation and determined as ‘low’; PlGF <12pg/ml, the lowest limit of detection for the assay and 
determined as ‘very low’.
These categorical groups were used based on the  evidence that ‘low’ PlGF has a high diagnostic 
accuracy (0.96; 95% confidence interval, 0.89–0.99) and negative predictive value (0.98; 0.93–0.995) 
of determining preeclampsia requiring delivery in 14 days in prospective observational cohort 
studies11, and ‘very low’ PlGF is the lowest limit of detection of the assay. We have previously 
reported that a fixed PlGF threshold of <100pg/mL predicted preeclampsia requiring delivery within 
14 days or before 37 weeks’ gestation (whichever was sooner) with sensitivity and negative 
predictive values similar to diagnostic accuracy estimates obtained by using a <5th centile cut-off.11 
The data were analysed according to their measured PlGF group. To describe clinical phenotype by 
measured PlGF level, demographic data are presented in the concealed testing group only. We 
compared how outcomes were influenced by trial arm in each subgroup in order to determine which 
groups of women benefited in our primary trial, and elucidate how this was achieved. 
Outcomes were adjusted for centre and categorical time effects because of the trial design. Effects 
were estimated using multiple regression including terms for the intervention with fixed effects 
using dummy variables at each time in each centre. Centre was considered as a categorical variable 
and fitted as separate dummy variables for each centre. Calendar time was treated as a single 
categorical time variable. Continuous outcomes were assessed by linear regression. All binary 
outcomes were analysed using a binomial regression model with a log link. Test performance was 
evaluated using sensitivity, specificity, positive and negative predictive values and positive and 
negative likelihood ratios and area under the receiver operating characteristic curves. Mixed effects 
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log-normal regression curves were generated for the proportion of women diagnosed relative to 
time from trial entry. 
Results
1006 women were included in this secondary analysis: 435 in the usual care group, and 571 in the 
revealed group (Figure 1). The unequal size of the trial groups was due to the stepped wedge design, 
such that recruitment increased overall as the trial continued.  There was no contamination between 
trial groups. Among the participants, 236 (23.5%) had PlGF <12pg/ml, 385 (38.3%) had PlGF 12-
100pg/ml, and 385 (38.3%) had PlGF >100pg/ml. 
Clinical characteristics by PlGF category 
In the concealed PlGF <12pg/ml category, 66% of women received a final diagnosis of preeclampsia. 
The mean highest systolic blood pressure in the 48 hours prior to trial entry in all women was 150 
(17) mmHg. The median gestation at delivery was 34.4 weeks, and 59% of the participants delivered 
within 14 days of enrolment to the trial. Of the babies born to women in the PlGF <12pg/ml 
category, 46% had a birthweight of <10th centile. 
In the concealed PlGF 12-100pg/ml category, 37% of women received a diagnosis of preeclampsia. 
The mean highest systolic blood pressure in the 48 hours prior to trial entry was 144 (19) mmHg. The 
median gestation at delivery was 37.4 weeks, with 43% of participants delivered within 14 days of 
enrolment in the trial. 20% of the babies born to women in the PlGF 12-100pg/ml category had a 
birthweight of <10th centile.
In the concealed PlGF >100pg/ml category, 12% of women received a final diagnosis of 
preeclampsia. The mean highest systolic blood pressure in the 48 hours prior to trial entry was 136 
(21) mmHg. The median gestation at delivery was 38.2 weeks, with 8% of participants delivered 
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within 14 days of enrolment in the trial. 9% of the babies born to women in the PlGF >100pg/ml 
category had a birthweight of <10th centile. Further demographic details and corresponding values 
for the revealed group are presented in table 1 and table S1. 
Diagnosis of Preeclampsia
The proportion of women diagnosed with preeclampsia was not significantly different between the 
intervention (revealed) and usual care (concealed) in any of the PlGF categories (74% vs 66% for PlGF 
<12pg/ml, 40% vs 37% for PlGF 12-100pg/ml, and 12% vs 10% for PlGF >100pg/ml) (Figure 2). 
Time to diagnosis of preeclampsia was lower in the revealed PlGF testing group (1.9 days) compared 
to usual care (4.1 days) across all three PlGF groups (time ratio 0.36, 95% CI 0.15–0.87; p=0.027). 
Within PlGF categories, time to diagnosis in the revealed testing group vs. the concealed testing 
group was 1.0 vs 2.0 days (adjusted time ratio 0.17 (95% CI 0.03-1·06)) for PlGF <12pg/ml; 2.0 vs 4.6 
days (adjusted time ratio 0.66 (95% CI 0.09-4.95)) for PlGF 12-100pg/ml, and 22.8 vs 30.3 days 
(adjusted time ratio 0.13 (95% CI 0.16-1.07)) for PlGF >100pg/ml) (Table 2). Figure S2 shows the 
mixed-effects lognormal regression curves with the proportion of women diagnosed by time from 
trial entry and differences in days (A), and weeks (B) with revealed PlGF testing in those women with 
PlGF <12pg/ml and PlGF 12-100pg/ml, showing shortened time to diagnosis in both PlGF <12pg/ml 
or PlGF 12-100pg/ml categories.
Maternal Outcomes
Severe maternal adverse outcomes were less frequent with revealed PlGF testing than with usual 
care overall (22/573 (3.8%) versus 24/446 (5.4%); adjusted OR (aOR) 0.32, 95%CI 0.11-0.95). This 
was significant in women with PlGF 12-100pg/ml (3.8% vs 6.9%; aOR 0.15 (95% CI 0.03-0.92)) (Table 
2, Table S2). There were no significant differences seen in mean systolic or diastolic blood pressure, 
or the use of magnesium sulfate in the revealed compared to concealed groups in any of the PlGF 
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categories (table 1). There was an increase seen in the use of antihypertensive medication in the 
intervention groups versus the usual care group in women with PlGF <12pg/ml (83.1% vs 74.5%; aOR 
3.85 (95% CI 1.03 to 8.28). There were no differences seen in the number of antenatal ultrasound 
scans, vaginal deliveries, or elective or emergency caesarean section rates between the intervention 
or usual care groups in any of the PlGF categories. 
Time to Delivery and Steroid Administration
PlGF categorisation stratified by time to delivery is shown in Figure 3; those with PlGF <12pg/ml, and 
<100pg/ml had consistently shorter times to delivery when compared to PlGF >100pg/ml. 
In women who delivered <35 weeks’ gestation, antenatal corticosteroids were given within the 
seven days prior to delivery in 39% (29/75) of the intervention group vs 16% (6/38) of the control 
group in women with PlGF <12pg/ml, and in 37.5% (12/32) and 26% (5/19) respectively in women 
with PlGF 12-100pg/ml. ). 
Perinatal Outcomes
There was no evidence of a difference significant difference in gestation at delivery, or perinatal 
adverse outcome rates with the intervention versus usual care in any of the PlGF categories (Table 3, 
Table S3). The difference in gestational age between the intervention and usual care in the <12pg/ml 
category was not significant (mean difference -0.03 weeks; -1.72 to 1.66). There were no significant 
differences in preterm delivery rates (<37 weeks’ gestation), or birthweight centiles between the 
intervention and usual care in any of the PlGF categories. 
Discussion
In one of the largest studies of angiogenetic markers for the assessment of women with suspected 
preterm preeclampsia to date, we have confirmed that in a real-world setting, low and very low PlGF 
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categories accurately identified women with a phenotype of more severe preeclampsia. Women 
with low and very low PGF concentrations have more marked hypertension, a greater number of 
adverse maternal outcomes, a shorter time to delivery interval and an increased need for preterm 
delivery, and higher rates of small for gestational age infants when compared with women with 
normal PlGF concentrations. Women with normal PlGF results have longer time to delivery intervals 
and rates of small for gestational age infants consistent with the general pregnant population. 
PlGF testing does not lead to significantly more cases of preeclampsia being diagnosed, but 
consistently shortens the time it takes for a clinician to make a diagnosis across all three categories 
of PlGF. After adjustment for baseline characteristics, gestational age at delivery was not 
significantly different between the groups. PlGF testing did not appear to cause a significant 
difference in gestation at delivery by causing or preventing a non-indicated intervention through 
knowledge of the result.  
Despite initial antenatal visit characteristics being very similar across all groups, women with very 
low PlGF concentrations had the most severe clinical phenotype of preeclampsia at entry to our 
study. However, whilst women with low PlGF concentrations appear to have an intermediate-risk 
phenotype of preeclampsia, they remain at increased risk of experiencing severe adverse outcomes 
compared to those with normal PlGF. One of the aims of stratification was to explore the 
mechanism(s) underlying the reduction seen in severe maternal adverse events with 
implementation of revealed PlGF testing. We found that the difference seen in the severe maternal 
adverse outcome composite was most marked in the PlGF 12-100pg/ml group (aOR 0.15 (95% CI 
0.03 to 0.92) and we anticipate that this may offer clinicians an opportunity to identify women at 
risk of developing severe preeclampsia complications, who may otherwise be considered at lower 
risk. 
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The improvement in clinical outcomes in this group may have been mediated by the use of the 
clinical management algorithm, which recommends increasing antenatal surveillance. Given that the 
proportion of women receiving a diagnosis is not increased with revealed PlGF, but that a diagnosis 
is made sooner after presentation, it would be reasonable to hypothesise that the mechanism for 
this reduction is mediated through increased surveillance and monitoring as recommended by the 
trial management algorithm. This may be particularly important in the group of women with PlGF 
12-100pg/ml who presented with clinical features of gestational hypertension but may also have had 
sub-clinical multi-organ disease features. 
In this study we reiterated that a low or very low PlGF was not an indication for delivery in itself as 
highlighted by previous studies.19 In the PlGF <12 mg/ml group, women in the revealed group appear 
to deliver around one week earlier than those in the masked group (33.4 vs 34.4 weeks), but after 
pre-specified adjustment for baseline characteristics, this was not significant. It is also possible that 
within each PlGF category, those who needed earlier delivery were appropriately managed, and 
those clinically well were monitored, improving outcomes but not significantly changing overall 
preterm birth rates. However, whilst implementation of revealed PlGF testing does not significantly 
alter gestation at delivery between the two trial groups overall, we cannot exclude a difference in 
increasing preterm birth in the very low PlGF category that we were underpowered to demonstrate 
in this study. The results of the PREPARE study, which aims to determine if the use of sFlt/PlGF and a 
risk stratification algorithm reduces preterm delivery rates, are awaited.20 
Whilst the algorithm did not recommend routine admission for women with low or very low PlGF, 
and made no recommendations regarding steroid administration or timing of delivery which was left 
to the discretion of the treating clinicians, we hypothesise that low PlGF may have acted as an early 
warning sign of impending complications, giving clinicians the opportunity to act accordingly. The 
finding of the INSPIRE trial, in which women with suspected preeclampsia were individually 
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randomised to revealed or concealed sFlt-1/PlGF testing demonstrated similar results, that the 
clinical use of PlGF/sFlt-1 testing enabled more accurate admission rates of high-risk patients 
without changing admission rates overall, and improved identification of those with preeclampsia.21
There was a high prevalence of respiratory distress requiring NNU admission (nearly 30%) among 
babies with a PlGF <12pg/ml, but this was driven by gestational age at delivery. Of those women 
who delivered <35 weeks’ gestation, revealed PlGF testing was associated with improvements in 
antenatal steroid administration within the seven days prior to delivery. Overall, 17% more women 
in the intervention (revealed) group received steroids within the seven days prior to delivery in those 
delivering <35 weeks’ gestation, demonstrating that PlGF may be clinically useful in assisting with 
the timing of steroid administration.
Given that PARROT was a national, multicentre trial, we would anticipate that the prevalence of 
disease seen in the trial population would be similar in women presenting with suspected preterm 
preeclampsia to maternity triage settings throughout the UK. This would support the generalisability 
of these findings to the wider UK population. 
A particular strength of our study is that these analyses focussed on identifying how the use of PlGF 
impacts on patient management pathways to influence important patient outcomes. This was a 
large multicentre study evaluating PlGF testing in a pragmatic way to achieve maximum external 
validity. The Patient Centred Outcomes Research Institute recommends the evaluation of process of 
care outcomes alongside morbidity outcomes in the evaluation of novel diagnostic tests.22 It is 
known that effectiveness trials (i.e. in a real-world clinical care setting) can assess the overall 
performance of an intervention, but that it can be difficult to identify the exact processes that 
explain the effectiveness of an intervention, due their pragmatic nature.23  Our cost effectiveness 
analysis has been previously reported. The resource use data showed that PlGF was overall cost 
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saving, with an increase in antenatal inpatient costs for those with abnormal PlGF alongside a 
reduction in outpatient attendances in those with a normal result, suggesting improved risk 
stratification with PlGF testing.24  As we did not undertake a more detailed process evaluation, the 
exact components of changes in the antenatal care pathways that contributed to the reduction in 
severe maternal adverse outcomes may remain unclear. However, this is balanced by the results 
being considerably more generalisable than if the trial had been undertaken with a very proscriptive 
management algorithm and multiple checkpoints such that the effect of the intervention might have 
required these additional components. Finding a significant effect size with a pragmatic algorithm 
suggests that clinicians found the intervention easy to integrate into their clinical care. 
Stratification of the women in to six groups based on PlGF concentrations and treatment allocation 
has created smaller numbers in each comparison group, meaning we may be underpowered to 
demonstrate important differences in care. This was a planned secondary analysis of an existing trial 
dataset, and as such the interpretation of the results should be circumspect. 
Previous comparative analyses of concealed versus revealed PlGF testing have demonstrated a 
reduction in perinatal deaths, but these analyses have been between two separate cohort studies 
with differing inclusion criteria, with a mixture of revealed and concealed testing.25 This trial showed 
no difference in perinatal deaths with revealed testing; we anticipate that one reason for this is that 
55% of the stillbirths in our trial occurred in pre-viable babies (<24 weeks’ gestation and <500 
grams), where intervention to influence outcome is limited. It may be that in order to prevent viable 
stillbirth, repeated PlGF testing is needed alongside ultrasound scanning as a means of disease 
monitoring, in order that interventions (including delivery) can be implemented in a timely manner 
in those babies at greatest risk of stillbirth. Further research is needed to determine the optimal 
frequency of repeat testing and to evaluate the impact on perinatal outcomes.
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Conclusions
This analysis has shown that the use of revealed PlGF testing with appropriate risk stratification of 
women, particularly in those with low or very low PlGF, can prevent serious maternal adverse 
outcomes. PlGF is beneficial in identifying women with a phenotype indicative of placentally-driven 






Figure 1. STROBE Diagram showing participant flow
Figure 2. Final Diagnoses for Women in the PARROT Trial, stratified by PlGF category.
Figure 3: Time to Delivery (Median, IQR) stratified by PlGF concentration for all participants. Red line indicates PlGF <12pg/ml; orange line, PlGF 12-





















































































Interval from test to delivery (days)
Interval from test to delivery (days)
Median (IQR)




Very Low PlGF (<12 pg/ml) 12 (6-22)
Low PlGF (12-100 pg/ml) 26 (16-36)
Normal PlGF (>100 pg/ml) 50 (32-75)
Usual Care
Very Low PlGF (<12 pg/ml) 17 (7-25)
Low PlGF (12-100 pg/ml) 27 (18-35)
Normal PlGF (>100 pg/ml) 50 (35-76)
35+0 to 36+6 weeks
PlGF Revealed 
Very Low PlGF (<12 pg/ml) 4 (2-8)
Low PlGF (12-100 pg/ml) 13 (7-18)
Normal PlGF (>100 pg/ml) 20 (13-28)
Usual Care
Very Low PlGF (<12 pg/ml) 8 (5-12)
Low PlGF (12-100 pg/ml) 11 (4-18)
Normal PlGF (>100 pg/ml) 21 (11-28)
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Age (years) Mean (SD) 31.6 (6.0) 31.0 (6.1) 32.3 (6.0) 32.1 (5.7) 31.7 (5.8) 31.2 (6.4)















Gestation at enrolment, weeks, 
median (IQR) 32.3 (28.7,34.3) 34.1 (29.1,35.9) 34.6 (32.4,35.9) 35.1 (33.1,36.1) 32.6 (29.1,34.9) 32.3 (28.9,34.7)
Primiparous (%) 84 (64.6%) 62 (58.5%) 114 (53.8%) 85 (49.1%) 114 (49.8%) 58 (37.2%)
Pre-existing chronic hypertension 20 (15.4%) 15 (14.2%) 29 (13.7%) 28 (16.2%) 37 (16.2%) 25 (16.0%)
Previous preeclampsia (%) 24 (18.5%) 23 (21.7%) 42 (19.8%) 34 (19.7%) 33 (14.4%) 33 (21.2%)
Highest blood pressure in 48 hours 















Time to diagnosis of preeclampsia 
(for those diagnosed) (days)
Median (IQR)
Effect size (time ratio (95%CI)) 
1.0 (0.3, 4.5) 2.0 (0.3, 9.0)
0.17 (0.03 – 1.06)
2.0 (0.9, 8.70) 4.6 (1.0, 14.5)
0.66 (0.09-4.95)
22.8 (8.4, 39.2) 30.3 (5.9, 65.1)
0.13 (0.16-1.07)
Number of women diagnosed 
with preeclampsia n (%) 96 (73.8%) 70 (66.0%) 84 (39.6%) 64 (37.4%) 23 (10.1%) 19 (12.3%)
Severe preeclampsia (ACOG definition) 
n women (%) 73 (56.2%) 49 (46.2%) 64 (30.2%) 49 (28.3%) 18 (7.9%) 7 (4.5%)
22



















Maternal adverse outcomes n of 
women (%) *
aOR (95% CI)
8 (6.2%) 6 (5.7%)
0.87 (0.09 to 8.02)
8 (3.8%) 12 (6.9%)
0.15 (0.03 to 0.92)
6 (2.6%) 6 (3.8%)
0.29 (0.02 to 4.34)
Use of antenatal corticosteroids for 
fetal lung maturity n (%) 98 (75.4%) 54 (50.9%) 67 (31.6%) 51 (29.5%) 35 (15.3%) 22 (14.1%)
Those delivering <35 weeks, % who 
got steroids in 7 days
29/75 (39%) 6/38 (16%) 12/32 (37.5%) 5/19 (26%) 3/6 (50%) 1/5 (20%)
Gestation at delivery, weeks 
Mean (SD)
Mean Difference (95% CI)
33.4 (3.13) 34.4 (3.72)
-0.03 (-1.72 to 1.66)
36.71 (2.48) 37.06 (2.04)
-0.40 (-1.25 to 0.45)
38.30 (1.75) 38.23 (2.33)
0.36 (-0.44 to 1.16)
Status at Birth n (%)
Livebirth
Stillbirth



















Birthweight centile by INTERGROWTH
Mean (SD)
Mean Difference (95% CI)
19.8 (22.4) 25.0 (28.8)
2.2 (-10.8 to 15.2)
41.5 (31.8) 44.1 (32.4)
-2.2 (14.0 to 9.5)
57.1 (31.5) 54.8 (30.9)
3.1 (-9.3 to 15.4)
Birthweight centile <10th 
aOR (95% CI)
54 (42%) 48 (46%)
0.44 (0.15 to 1.27)
47 (22.4%) 35 (20.2%)
0.90 (0.33 to 2.48)
23 (10.1%) 14 (9.0%)
1.85 (0.45 to 7.67)
Neonatal unit admission n (%)
aOR (95% CI)
93 (71.5%) 62 (58.5%)
2.37 (0.63-7.92)
73 (34.4%) 54 (31.2%)
2.37 (0.76-7.37)
29 (12.7%) 27 (17.3%)
Perinatal adverse outcome, n of 
infants (%) **
aOR (95% CI)
49 (37.7%) 27 (25.5%)
1.95 (0.64 to 6.00)
25 (11.8%)  23 (13.5%)
1.62 (0.45 to 5.89)
12 (5.2%) 9 (5.8%)
3.84 (0.29 to 51.31)
*As defined by the fullPIERS consensus14 (number of women with one or more of the following features; maternal death, eclampsia, Glasgow Coma Scale 
<13, stroke, transient ischaemic attack, cortical blindness, posterior reversible encephalopathy, retinal detachment, positive inotropic support, infusion of 
third parenteral antihypertensive, myocardial ischaemia or infarction, blood oxygen saturations <90%, 50% FiO2 for > 1 hour, intubation (other than for 
23
caesarean section), pulmonary oedema, ionotropic support, transfusion of blood products, platelets <50x109 per litre, hepatic dysfunction, haematoma or 
rupture, severe acute kidney injury (creatinine >150 µmol/L  or >200 µmol/L  in chronic kidney disease, dialysis, placental abruption)).
**Number of babies with one or more of the following features: perinatal death, late neonatal death (8-27 completed days of life), necrotising enterocolitis 
(stage 2 or 3), respiratory distress syndrome, bronchopulmonary dysplasia, seizures, retinopathy of prematurity, intraventricular haemorrhage.
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